• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book Apps
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Modern Challenges of Delusional Disorder

Modern Challenges of Delusional Disorder

September 3, 2020
Joseph Pierre, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Joseph Pierre, MD. Chief, Hospital Psychiatry Division at the VA West Los Angeles Healthcare Center. Clinical Professor in the Department of Psychiatry and Biobehavioral Sciences at UCLA. Dr. Pierre has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

While positive symptoms like hallucinations and delusions are among the more treatment-responsive symptoms of schizophrenia, the treatment of delusional disorder often proves much more vexing.

Delusional disorder is often a diagnosis of exclusion requiring that you rule out other causes like schizophrenia, primary mood disorder, or substance-induced psychosis. The DSM criteria for delusional disorder have changed over time, with DSM-5 no longer specifying the need for “non-bizarre” delusions. The distinction between “bizarre” and “non-bizarre” delusions was removed due to poor inter-rater reliability (Bell V et al, Schizophr Res 2006;86(1–3):76–79).

The DSM-5 criteria for delusional disorder specify that “apart from the impact of the delusion(s) or its ramifications, functioning is not markedly impaired.” However, the functional impairment resulting from a patient’s delusions can be profound. Still, the criteria reflect the fact that those with delusional disorder, unlike many suffering from schizophrenia, are typically able to hold down jobs and can participate in family life. Often people with delusional disorder avoid psychiatrists, instead bringing their complaints to the legal system, non-psychiatric medical providers, spouses, or the internet.

The internet presents another challenge in assessing delusions. Delusions aren’t typically considered to be shared beliefs, but in the internet era, people with conspiracy theories as well as full-blown delusions can find like-minded supporters online in a way that previously did not exist (Pierre JM, J Am Acad Psychiatry Law 2019;47(2):171–179).

For example, delusions of persecution can be easily validated on the internet as examples of widespread “gangstalking” (Sheridan LP et al, J Forens Psychiatr Psychol 2015;26(5):601–623). People with delusions of infestation can find a non-psychiatric explanation for their experiences in the form of “Morgellons disease,” a controversial syndrome consisting of fibrous skin sores and the sensation of bugs inside the skin (Hylwa SA et al, Clin Dermatol 2018;36(6):714–718; more on Morgellons is in our 9/16/2020 podcast). Although those with delusional disorder find such online support helpful, it often prevents them from receiving the potential benefits of psychiatric care.

Clinical diversity
Delusions tend to center around stereotyped themes of paranoia, grandiosity, somatic experiences, jealousy, and erotomania. In this sense, they often seem to represent hypertrophied traits and anxieties that we all can recognize in ourselves to some degree. Examples include a married man who accuses his wife of cheating and follows her around with a camera to collect “evidence” of her infidelity; a group of men and women who meet in a support group for “targeted individuals” to discuss how to cope with surveillance and harassment by the government; or a father who, after a stroke, is convinced that his family has been replaced by imposters.

Given the diversity of experiences that fall under the definition of a delusion, including the various “misidentification syndromes” (eg, Capgras, Fregoli, and Cotard syndromes; xenomelia; etc), it should come as no surprise that an overarching pathophysiology of delusions remains beyond our grasp. However, there is evidence that some cognitive biases are associated with delusional thinking more generally. One of the most replicated findings is that those with delusional beliefs tend to have a “jumping to conclusions” cognitive style, making decisions based on comparatively little evidence (Dudley R et al, Schiz Bull 2016;42(3):652–665). This finding helps to explain why people with delusions often make hasty conclusions based on first impressions and singular subjective experiences. In clinical practice, this often stymies clinicians’ abilities to rationally discuss other potential explanations of patients’ life events, including somatic experiences attributed to medication side effects.

Treatment alliance
Psychiatric treatment generally goes better when it’s built around a therapeutic alliance, and nowhere is that more true than in delusional disorder. Getting patients “in the door” and keeping them engaged requires empathic listening to their idiosyncratic accounts of their experiences and sources of distress. When patients inevitably ask whether you believe their delusions, it is best to emphasize that you understand their suffering is real and not just evidence that they’re “crazy.” This creates an opportunity to address symptoms like anxiety and insomnia now. Later, as the relationship builds, you can examine and challenge the evidence for their beliefs together.


Patients rarely disavow their delusions, even in recovery. More often they’ll say things like, “I just don’t think about it much anymore,” or, “I was infected with parasites, but they’re mostly gone now.” Focusing less on the delusional content and more on functional outcomes like work and relationships is key to successful long-term collaboration.


Pharmacotherapy
Antipsychotics are the default treatment for delusions, but the evidence for their use here is shakier than you might think. While patients with delusional disorder are occasionally included in antipsychotic clinical trials, there has never been a randomized controlled trial (RCT) of any pharmacologic intervention ­exclusively for the treatment of patients with delusional disorder.


What we do have in lieu of RCTs are case reports, uncontrolled observations, and non-randomized trials, and even here the results are often modest. Overall, only about a third of patients with delusional disorder have significant improvement on antipsychotics (ie, > 50% reduction in symptoms) (Munoz-Negro J et al, J Clin Psychopharmacol 2016;36(6):684–690).



Delusional Disorder: Quick Take


Table: Delusional Disorder: Quick Take


(Click to view full-size PDF.)



Outcomes with first-generation antipsychotics are slightly better than second-generation atypicals, but it’s hard to draw conclusions without head-to-head RCTs. Their apparent superiority may be due to the specific benefits of pimozide in delusional parasitosis, which might be explained by its ability to decrease cutaneous sensations via opioid and antihistaminergic antagonisms. However, given the potential for extrapyramidal side effects and QTc prolongation, pimozide is no longer considered a first-line medication for delusional disorder, even for delusional infestation (Moriarty N et al, Am J Med 2019;132(12):1401–1409). Among the atypicals, risperidone and ­olanzapine are often recommended first-line because they have the most research supporting them, but that recommendation ignores tolerability issues—particularly metabolic—that may guide you toward other atypicals.


There are at least three reasons why antipsychotics may not work as well in delusional disorder as they do in schizophrenia (Peralta V et al, Psychol Med 2016;46(13):2829–2839):



  1. Treatment adherence is often poor, as evidenced by better response rates during inpatient care (­Munoz-Negro J et al, J Clin Psychopharmacol 2020). This is clearly the most significant challenge to the successful treatment of delusional disorder.

  2. There are many subtypes of delusional disorder, and it may be that some—such as delusions of infestation or jealousy—are more responsive to antipsychotics than others.

  3. Delusions are ultimately considered to be beliefs, so it may therefore be unrealistic to expect that antipsychotic treatment would fundamentally change delusions any more than we would expect it to modify our strong convictions about politics or religion.


Psychotherapy
When it comes to evidence in delusional disorder, psychotherapy actually has a leg up on medication. In the only RCT done in delusional disorder to date, cognitive behavioral therapy (CBT) improved conviction, preoccupation, insight, affect, and other dimensions of delusional belief as compared to supportive sessions within a small sample of those already taking antipsychotic medications (O’Connor K et al, Can J Psychiatry 2007;52(3):182–190). However, for delusions across various psychotic disorders (eg, not only in delusional disorder), a meta-analysis found that the benefits of CBT were short lived and were not superior to other forms of psychotherapy (Mehl S et al, Front Psychol 2015;6:1450).


TCPR Verdict: Combined psychotherapy and antipsychotic medication is the ideal approach in delusional disorder. Change is difficult and adherence is low in this population. Focus on a therapeutic alliance around the patient’s goals. Start with an atypical antipsychotic that is tolerable enough for the patient to stick with and can help address the symptoms like anxiety and insomnia. Antipsychotics may not work as well in delusional disorder as they do in schizophrenia, and they are not necessary if they are not helping.

General Psychiatry
KEYWORDS antipsychotics delusional-disorder forensic psychiatry pimozide psychosis psychotic-depression schizophrenia
    Joseph Pierre, MD.

    More from this author
    www.thecarlatreport.com
    Issue Date: September 3, 2020
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - When to Use Lithium, TCPR, September 2020
    Highlights From This Issue
    How COVID-19 Affects the Brain
    Who Should Get Lithium?
    Modern Challenges of Delusional Disorder
    Two Augmentation Strategies Compared in Bipolar I
    Confidentiality in a Time of COVID
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2635946985.jpg
      General Psychiatry

      AI in Practice

      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.